Botulinum neurotoxin versus tizanidine in upper limb spasticity: A placebo-controlled study

D. M. Simpson, J. M. Gracies, S. A. Yablon, R. Barbano, A. Brashear, T. B.S. Team

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Background: While spasticity is commonly treated with oral agents or botulinum neurotoxin (BoNT) injection, these treatments have not been systematically compared. Methods: This study performed a randomised, doubleblind, placebo-controlled trial to compare injection of BoNT-Type A into spastic upper limb muscles versus oral tizanidine (TZD), or placebo, in 60 subjects with upperlimb spasticity due to stroke or traumatic brain injury (TBI). Wrist flexors were systematically injected, while other upper limb muscles were injected as per investigator judgement. Participants were randomised into three groups: (1) intramuscular BoNT plus oral placebo; (2) oral TZD plus intramuscular placebo; (3) intramuscular placebo plus oral placebo. The primary outcome was the difference in change in wrist flexor modified Ashworth score (MAS) between groups. Other outcome measures included MAS at elbow and finger joints, Disability Assessment Scale (DAS) and adverse events (AE). Results: BoNT produced greater tone reduction than TZD or placebo in finger and wrist flexors at week 3 (p,0.001 vs TZD; p,0.02 vs placebo) and 6 (p=0.001 vs TZD; p = 0.08 vs placebo), and greater improvement in the cosmesis domain of the DAS at week 6 (p,0.01). TZD was not superior to placebo in tone reduction at either time point (p≥0.09). The incidence of AE related to study treatment was higher with TZD than in the BoNT (p,0.01) or placebo groups (p = 0.001). Conclusions: BoNT is safer and more effective than TZD in reducing tone and disfigurement in upper-extremity spasticity, and may be considered as first-line therapy for this disorder.

Original languageEnglish (US)
Pages (from-to)380-385
Number of pages6
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume80
Issue number4
DOIs
StatePublished - Apr 1 2009
Externally publishedYes

Fingerprint

Neurotoxins
Upper Extremity
Placebos
Wrist
tizanidine
Finger Joint
Elbow Joint
Muscles
Injections
Muscle Spasticity
Fingers
Therapeutics
Stroke
Research Personnel
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Botulinum neurotoxin versus tizanidine in upper limb spasticity : A placebo-controlled study. / Simpson, D. M.; Gracies, J. M.; Yablon, S. A.; Barbano, R.; Brashear, A.; Team, T. B.S.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 80, No. 4, 01.04.2009, p. 380-385.

Research output: Contribution to journalArticle

Simpson, D. M. ; Gracies, J. M. ; Yablon, S. A. ; Barbano, R. ; Brashear, A. ; Team, T. B.S. / Botulinum neurotoxin versus tizanidine in upper limb spasticity : A placebo-controlled study. In: Journal of Neurology, Neurosurgery and Psychiatry. 2009 ; Vol. 80, No. 4. pp. 380-385.
@article{a1013a63a211494db90932c5169aab93,
title = "Botulinum neurotoxin versus tizanidine in upper limb spasticity: A placebo-controlled study",
abstract = "Background: While spasticity is commonly treated with oral agents or botulinum neurotoxin (BoNT) injection, these treatments have not been systematically compared. Methods: This study performed a randomised, doubleblind, placebo-controlled trial to compare injection of BoNT-Type A into spastic upper limb muscles versus oral tizanidine (TZD), or placebo, in 60 subjects with upperlimb spasticity due to stroke or traumatic brain injury (TBI). Wrist flexors were systematically injected, while other upper limb muscles were injected as per investigator judgement. Participants were randomised into three groups: (1) intramuscular BoNT plus oral placebo; (2) oral TZD plus intramuscular placebo; (3) intramuscular placebo plus oral placebo. The primary outcome was the difference in change in wrist flexor modified Ashworth score (MAS) between groups. Other outcome measures included MAS at elbow and finger joints, Disability Assessment Scale (DAS) and adverse events (AE). Results: BoNT produced greater tone reduction than TZD or placebo in finger and wrist flexors at week 3 (p,0.001 vs TZD; p,0.02 vs placebo) and 6 (p=0.001 vs TZD; p = 0.08 vs placebo), and greater improvement in the cosmesis domain of the DAS at week 6 (p,0.01). TZD was not superior to placebo in tone reduction at either time point (p≥0.09). The incidence of AE related to study treatment was higher with TZD than in the BoNT (p,0.01) or placebo groups (p = 0.001). Conclusions: BoNT is safer and more effective than TZD in reducing tone and disfigurement in upper-extremity spasticity, and may be considered as first-line therapy for this disorder.",
author = "Simpson, {D. M.} and Gracies, {J. M.} and Yablon, {S. A.} and R. Barbano and A. Brashear and Team, {T. B.S.}",
year = "2009",
month = "4",
day = "1",
doi = "10.1136/jnnp.2008.159657",
language = "English (US)",
volume = "80",
pages = "380--385",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Botulinum neurotoxin versus tizanidine in upper limb spasticity

T2 - A placebo-controlled study

AU - Simpson, D. M.

AU - Gracies, J. M.

AU - Yablon, S. A.

AU - Barbano, R.

AU - Brashear, A.

AU - Team, T. B.S.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Background: While spasticity is commonly treated with oral agents or botulinum neurotoxin (BoNT) injection, these treatments have not been systematically compared. Methods: This study performed a randomised, doubleblind, placebo-controlled trial to compare injection of BoNT-Type A into spastic upper limb muscles versus oral tizanidine (TZD), or placebo, in 60 subjects with upperlimb spasticity due to stroke or traumatic brain injury (TBI). Wrist flexors were systematically injected, while other upper limb muscles were injected as per investigator judgement. Participants were randomised into three groups: (1) intramuscular BoNT plus oral placebo; (2) oral TZD plus intramuscular placebo; (3) intramuscular placebo plus oral placebo. The primary outcome was the difference in change in wrist flexor modified Ashworth score (MAS) between groups. Other outcome measures included MAS at elbow and finger joints, Disability Assessment Scale (DAS) and adverse events (AE). Results: BoNT produced greater tone reduction than TZD or placebo in finger and wrist flexors at week 3 (p,0.001 vs TZD; p,0.02 vs placebo) and 6 (p=0.001 vs TZD; p = 0.08 vs placebo), and greater improvement in the cosmesis domain of the DAS at week 6 (p,0.01). TZD was not superior to placebo in tone reduction at either time point (p≥0.09). The incidence of AE related to study treatment was higher with TZD than in the BoNT (p,0.01) or placebo groups (p = 0.001). Conclusions: BoNT is safer and more effective than TZD in reducing tone and disfigurement in upper-extremity spasticity, and may be considered as first-line therapy for this disorder.

AB - Background: While spasticity is commonly treated with oral agents or botulinum neurotoxin (BoNT) injection, these treatments have not been systematically compared. Methods: This study performed a randomised, doubleblind, placebo-controlled trial to compare injection of BoNT-Type A into spastic upper limb muscles versus oral tizanidine (TZD), or placebo, in 60 subjects with upperlimb spasticity due to stroke or traumatic brain injury (TBI). Wrist flexors were systematically injected, while other upper limb muscles were injected as per investigator judgement. Participants were randomised into three groups: (1) intramuscular BoNT plus oral placebo; (2) oral TZD plus intramuscular placebo; (3) intramuscular placebo plus oral placebo. The primary outcome was the difference in change in wrist flexor modified Ashworth score (MAS) between groups. Other outcome measures included MAS at elbow and finger joints, Disability Assessment Scale (DAS) and adverse events (AE). Results: BoNT produced greater tone reduction than TZD or placebo in finger and wrist flexors at week 3 (p,0.001 vs TZD; p,0.02 vs placebo) and 6 (p=0.001 vs TZD; p = 0.08 vs placebo), and greater improvement in the cosmesis domain of the DAS at week 6 (p,0.01). TZD was not superior to placebo in tone reduction at either time point (p≥0.09). The incidence of AE related to study treatment was higher with TZD than in the BoNT (p,0.01) or placebo groups (p = 0.001). Conclusions: BoNT is safer and more effective than TZD in reducing tone and disfigurement in upper-extremity spasticity, and may be considered as first-line therapy for this disorder.

UR - http://www.scopus.com/inward/record.url?scp=64749110674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749110674&partnerID=8YFLogxK

U2 - 10.1136/jnnp.2008.159657

DO - 10.1136/jnnp.2008.159657

M3 - Article

C2 - 18977811

AN - SCOPUS:64749110674

VL - 80

SP - 380

EP - 385

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 4

ER -